trending Market Intelligence /marketintelligence/en/news-insights/trending/5nFlsTn1P13bmGasx2zNwA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Regeneron Q2 earnings up 10.6% YOY

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Regeneron Q2 earnings up 10.6% YOY

Regeneron Pharmaceuticals Inc. said its non-GAAP net income for the second quarter amounted to $690.0 million, an increase of 10.6% from $623.7 million in the prior-year period.

EPS climbed 10% year over year to $6.02 from $5.45.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter is $5.42.

The Tarrytown, N.Y.-based company booked total revenue of $1.93 billion, up 20% on an annual basis from $1.60 billion. Meanwhile, research and development expenses climbed 98.1% quarter over quarter to $1.05 billion from $529.3 million.

On a GAAP basis, net income decreased 65.0% to $193.1 million, or $1.68 per share, from $551.4 million, or $4.82 per share, in the year-ago quarter.